{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:23:02Z","timestamp":1791321782803,"version":"4.3.1"},"reference-count":131,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.semarthrit.2003.12.003","type":"journal-article","created":{"date-parts":[[2004,8,11]],"date-time":"2004-08-11T14:34:09Z","timestamp":1092234849000},"page":"465-483","source":"Crossref","is-referenced-by-count":91,"title":["The use of methotrexate in rheumatoid arthritis"],"prefix":"10.1016","volume":"34","author":[{"given":"Andrea T.","family":"Borchers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl L.","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurtej S.","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2003.12.003_BIB1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.1780390502","article-title":"Guidelines for the management of rheumatoid arthritis","volume":"39","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis","volume":"46","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.semarthrit.2003.12.003_BIB3","first-page":"S218","article-title":"Use of second line \u201cdisease modifying\u201d anti-rheumatic drugs (DMARDs) within 5 months of disease onset by 64% of 750 rheumatoid arthritis patients under care of 142 US rheumatologists","volume":"40","author":"Wolfe","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB4","first-page":"2331","article-title":"How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis","volume":"25","author":"Maetzel","year":"1998","journal-title":"J Rheumatol"},{"issue":"Suppl 18","key":"10.1016\/j.semarthrit.2003.12.003_BIB5","first-page":"S78","article-title":"Use of combination therapy in the routine care of patients with rheumatoid arthritis","volume":"17","author":"Hawley","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0162-3109(00)00189-2","article-title":"Mechanisms of action of methotrexate","volume":"47","author":"Genestier","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive properties of methotrexate","volume":"102","author":"Genestier","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB8","first-page":"1","article-title":"The mechanism of action of methotrexate in rheumatoid arthritis","volume":"21","author":"Kremer","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB9","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/art.1780391203","article-title":"Molecular therapeutics. Methotrexate and its mechanism of action","volume":"39","author":"Cronstein","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB10","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0049-0172(98)80049-8","article-title":"Methotrexate in rheumatoid arthritis","volume":"27","author":"van Ede","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB12","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/ard.61.12.1060","article-title":"Purine enzymes in patients with rheumatoid arthritis treated with methotrexate","volume":"61","author":"van Ede","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/art.1780350304","article-title":"Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"35","author":"Williams","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB15","first-page":"1008","article-title":"Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis","volume":"17","author":"Skeith","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB16","first-page":"1845","article-title":"A comparison of low dose methotrexate bioavailability","volume":"20","author":"Jundt","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2125.1993.tb04158.x","article-title":"The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis","volume":"35","author":"Seideman","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","article-title":"Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis","volume":"36","author":"Hamilton","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0049-0172(94)90027-2","article-title":"Low-dose methotrexate in rheumatic diseases\u2014efficacy, side effects, and risk factors for side effects","volume":"23","author":"Schnabel","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB20","article-title":"Methotrexate for treating rheumatoid arthritis [last amended 1997]","volume":"4","author":"Suarez Almazor","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/art.1780350202","article-title":"Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update","volume":"35","author":"Weinblatt","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/rheumatology\/36.5.535","article-title":"Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate","volume":"36","author":"Bologna","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/ard.58.2.79","article-title":"Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis","volume":"58","author":"Haagsma","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/ard.54.11.881","article-title":"Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients","volume":"54","author":"De La Mata","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/anr.1780320603","article-title":"Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment","volume":"32","author":"Alarc\u00f3n","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB26","first-page":"994","article-title":"Termination of slow acting antirheumatic therapy in rheumatoid arthritis","volume":"17","author":"Wolfe","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB27","first-page":"1885","article-title":"Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices","volume":"19","author":"Pincus","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/art.1780350203","article-title":"Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months","volume":"35","author":"Kremer","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB29","first-page":"1850","article-title":"Adverse effects of low dose methotrexate therapy in rheumatoid arthritis","volume":"20","author":"McKendry","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB30","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/ard.54.9.708","article-title":"Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients","volume":"54","author":"Alarc\u00f3n","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB31","first-page":"1881","article-title":"Long-term treatment of destructive rheumatoid arthritis with methotrexate","volume":"24","author":"Rau","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB32","first-page":"1864","article-title":"Longterm methotrexate use in rheumatoid arthritis","volume":"27","author":"Wluka","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB33","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/art.1780371013","article-title":"Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study","volume":"37","author":"Weinblatt","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB34","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB35","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","article-title":"Treatment with leflunomide slows radiographic progression of rheumatoid arthritis","volume":"43","author":"Sharp","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB37","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group","volume":"44","author":"Cohen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB38","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P","article-title":"Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis","volume":"42","author":"Weinblatt","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB39","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-137-9-200211050-00007","article-title":"Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Kremer","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB40","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1002\/1529-0131(200011)43:11<2609::AID-ANR32>3.0.CO;2-R","article-title":"Serious liver disease in a patient receiving methotrexate and leflunomide","volume":"43","author":"Weinblatt","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB41","series-title":"ACR Hotline 2002","article-title":"Reports of leflunomide hepatotoxicity in patients with rheumatoid arthritis","author":"Matteson","year":"2004"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB44","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB46","first-page":"1238","article-title":"Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis","volume":"28","author":"Moreland","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB47","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB48","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB49","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB50","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB51","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB52","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB53","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/art.10578","article-title":"Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis","volume":"46","author":"Nuki","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB54","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","article-title":"A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis","volume":"43","author":"Jiang","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB55","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.10456","article-title":"Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity","volume":"47","author":"Erkan","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0002-9343(02)01243-3","article-title":"Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis","volume":"113","author":"Wong","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB58","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/rheumatology\/37.6.612","article-title":"Combination therapy in rheumatoid arthritis","volume":"37","author":"Verhoeven","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB59","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O\u2019Dell","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB60","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/art.10228","article-title":"Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications","volume":"46","author":"O\u2019Dell","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB61","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis","volume":"353","author":"M\u00f6tt\u00f6nen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB62","first-page":"699","article-title":"Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis","volume":"17","author":"Calguneri","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB63","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB64","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM199507203330302","article-title":"The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group","volume":"333","author":"Kirwan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","article-title":"Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial","volume":"136","author":"van Everdingen","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB66","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/rheumatology\/37.9.930","article-title":"Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group","volume":"37","author":"Hickling","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB67","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.10083","article-title":"COBRA combination therapy in patients with early rheumatoid arthritis","volume":"46","author":"Landew\u00e9","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB68","first-page":"1868","article-title":"Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients","volume":"19","author":"Alarc\u00f3n","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB69","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/art.1780360307","article-title":"Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis","volume":"36","author":"Walker","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/art.1780360303","article-title":"The relative toxicity of disease-modifying antirheumatic drugs","volume":"36","author":"Fries","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB71","first-page":"1628","article-title":"Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis","volume":"17","author":"Furst","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB72","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB73","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/rheumatology\/37.10.1060","article-title":"A 36-month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis","volume":"37","author":"Menninger","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB74","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/rheumatology\/39.12.1374","article-title":"Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis","volume":"39","author":"van Jaarsveld","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/anr.1780320202","article-title":"Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples","volume":"32","author":"Kremer","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB76","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.1780390503","article-title":"Guidelines for monitoring drug therapy in rheumatoid arthritis","volume":"39","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB77","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1378\/chest.109.4.933","article-title":"Pulmonary function in patients receiving long-term low-dose methotrexate","volume":"109","author":"Cottin","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB78","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group","volume":"127","author":"Alarcon","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB79","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/art.1780390214","article-title":"Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis","volume":"39","author":"Gutierrez-Ure\u00f1a","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB80","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0002-9378(16)38924-4","article-title":"Therapeutic abortions with a folic acid antagonist, 4 aminopteroylglutamic acid (4-amino PGA) administered by the oral route","volume":"63","author":"Thiersch","year":"1952","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB81","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/tera.10052","article-title":"Fetal methotrexate and misoprostol exposure","volume":"66","author":"Wheeler","year":"2002","journal-title":"Teratology"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB82","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/qjmed\/92.10.551","article-title":"The effects of methotrexate on pregnancy, fertility and lactation","volume":"92","author":"Lloyd","year":"1999","journal-title":"QJM"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB83","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0029-7844(01)01607-6","article-title":"Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester","volume":"99","author":"Nguyen","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB84","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1046\/j.1365-2141.2002.03619.x","article-title":"Spontaneous remission of low-grade B-cell non-Hodgkin\u2019s lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis","volume":"118","author":"Baird","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB85","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/rheumatology\/36.11.1196","article-title":"The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases","volume":"36","author":"Furst","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB86","first-page":"2573","article-title":"Rheumatoid arthritis, methotrexate, and lymphoma","volume":"28","author":"Starkebaum","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB87","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","article-title":"The mortality of rheumatoid arthritis","volume":"37","author":"Wolfe","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB88","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/S0140-6736(00)02222-4","article-title":"Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity","volume":"355","author":"Landew\u00e9","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB89","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/oxfordjournals.aje.a008828","article-title":"Homocysteine metabolism and risk of myocardial infarction","volume":"143","author":"Verhoef","year":"1996","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB90","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.277.22.1775","article-title":"Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project","volume":"277","author":"Graham","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/art.1780380116","article-title":"Abnormal vitamin B6 status in rheumatoid cachexia","volume":"38","author":"Roubenoff","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0009-9120(98)00093-9","article-title":"Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women","volume":"32","author":"Hernanz","year":"1999","journal-title":"Clin Biochem"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB93","first-page":"459","article-title":"Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients","volume":"13","author":"Leeb","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB94","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/art.1780301205","article-title":"Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy","volume":"30","author":"Morgan","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB95","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.1780290703","article-title":"Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates","volume":"29","author":"Kremer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB96","first-page":"441","article-title":"Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis","volume":"2","author":"Morgan","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB97","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/rheumatology\/41.6.658","article-title":"Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis","volume":"41","author":"van Ede","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB98","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/art.1780400418","article-title":"Abnormal homocysteine metabolism in rheumatoid arthritis","volume":"40","author":"Roubenoff","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB99","first-page":"859","article-title":"Serum homocysteine and methylmalonic acid in patients with rheumatoid arthritis and cobalaminopenia","volume":"25","author":"Pettersson","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/030097401753180408","article-title":"Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid","volume":"30","author":"Slot","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB101","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/clpt.1989.179","article-title":"Fasting plasma homocysteine as a sensitive parameter of antifolate effect","volume":"46","author":"Refsum","year":"1989","journal-title":"Clin Pharmacol Ther"},{"issue":"Pt 1","key":"10.1016\/j.semarthrit.2003.12.003_BIB102","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/clpt.1991.180","article-title":"Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate","volume":"50","author":"Morgan","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB103","first-page":"36","article-title":"The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials","volume":"25","author":"Ortiz","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB104","series-title":"Cochrane Database Syst Rev","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","author":"Ortiz","year":"2002"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB105","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB106","first-page":"2110","article-title":"Folic acid alters methotrexate availability in patients with rheumatoid arthritis","volume":"27","author":"Bressolle","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB107","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.50.12.913","article-title":"Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid","volume":"50","author":"Joyce","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB108","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/art.1780310712","article-title":"The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients","volume":"31","author":"Tishler","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB109","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2340\/0001555572438440","article-title":"Folinic acid rescue used routinely in psoriatic patients with known methotrexate \u201csensitivity\u201d","volume":"72","author":"Hills","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB110","first-page":"1078","article-title":"Concurrent use of folinic acid and methotrexate in rheumatoid arthritis","volume":"15","author":"Hanrahan","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB111","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB112","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00003088-200342020-00003","article-title":"Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases","volume":"42","author":"Grim","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB113","first-page":"1356","article-title":"Methotrexate kinetics in rheumatoid arthritis","volume":"15","author":"Ahern","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB114","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00226329","article-title":"A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM","volume":"49","author":"Bressolle","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2125.2002.01621.x","article-title":"Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis","volume":"54","author":"Chl\u00e1dek","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB116","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002280050404","article-title":"Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment","volume":"53","author":"Chl\u00e1dek","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB117","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.57.2.110","article-title":"Effects of moderate renal insuficciency on pharmakokinetics of methotrexate in rheumatoid arthritis patients","volume":"57","author":"Bressolle","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB118","first-page":"38","article-title":"Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate","volume":"22","author":"Kremer","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB119","first-page":"218","article-title":"The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis","volume":"22","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB120","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/anr.1780320604","article-title":"Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis","volume":"32","author":"Wallace","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB121","first-page":"1573","article-title":"Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis","volume":"20","author":"Ravelli","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB122","first-page":"844","article-title":"Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis","volume":"22","author":"Lafforgue","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB123","first-page":"465","article-title":"Correlation between methotrexate pharmacokinetic parameters, and clinical and biological status in rheumatoid arthritis patients","volume":"13","author":"Bologna","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB124","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard.53.7.475","article-title":"Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis","volume":"53","author":"Lebbe","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1365-2125.1998.t01-1-00790.x","article-title":"The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis","volume":"46","author":"Godfrey","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB126","first-page":"313","article-title":"Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis","volume":"16","author":"Furst","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB127","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/rheumatology\/32.8.751","article-title":"Preliminary report. Methotrexate\u2014the relationship between dose and clinical effect","volume":"32","author":"Seideman","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB128","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/art.1780400229","article-title":"Guidelines for folate supplementation in rheumatoid arthritis patients treated with methotrexate","volume":"40","author":"Alarc\u00f3n","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/tera.10060","article-title":"Prevalence of spina bifida and encephaly during the transition to mandatory folic acid fortification in the United States","volume":"66","author":"Williams","year":"2002","journal-title":"Teratology"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB130","first-page":"962","article-title":"Folate status in women of childbearing age\u2014United States, 1999","volume":"49","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.semarthrit.2003.12.003_BIB131","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJM199502023320512","article-title":"Methotrexate for chronic diseases in adults","volume":"332","author":"Weinblatt","year":"1995","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017204001556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017204001556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T04:31:51Z","timestamp":1705206711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017204001556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":131,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0049017204001556"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2003.12.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}